Subscribe
Sarilumab (Kevzara) is a novel interleukin (IL)-6 receptor inhibitor that was approved by the US Food and Drug Administration (FDA) on May 22, 2017, for the treatment of adults with moderately or severely active RA who have had an inadequate response or intolerance to 1 or more DMARDs.

Results 1 - 1 of 1
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search